Medicines & Treatments
B7-33 6 mg
B7-33 6 mg – Peptide Hubs B7-33 is a synthetic peptide and selective analog of human relaxin-2, specifically designed to target and activate the RXFP1 receptor with minimized hormonal activity. The 6 mg lyophilized vial by Peptide Hubs offers researchers a highly stable, precise format for studying fibrotic conditions, cardiac and pulmonary remodeling, and wound healing responses. What Is B7-33? B7-33 is a single-chain variant of relaxin-2 that retains anti-fibrotic signaling via the RXFP1 receptor without triggering the reproductive or vasodilatory side effects typical of native relaxin. It is considered a promising candidate in the field of organ fibrosis, particularly in liver, heart, and lung tissues. Researchers value B7-33 for its ability to modulate TGF-β1 signaling and reduce tissue scarring. Mechanism of Action B7-33 selectively binds to the relaxin family peptide receptor 1 (RXFP1), stimulating downstream signaling pathways that reduce fibrotic activity and collagen deposition. Unlike full relaxin-2, it does not activate secondary receptors tied to systemic vasodilation or reproductive hormones. This selectivity makes B7-33 ideal for studies focused on anti-fibrotic outcomes. For in-depth biological data, see this NIH publication on B7-33. Research Applications B7-33 is used in preclinical research involving organ protection, tissue remodeling, and systemic or localized fibrotic disorders. It has been studied in models of myocardial infarction, pulmonary fibrosis, and kidney injury. Some experimental protocols also examine B7-33's synergy with compounds like BPC-157 and GHK-CU for regenerative medicine research.
B7-33 10 mg
Dragon Pharma B7-33 10 mg – Selective RXFP1 Agonist for Anti-Fibrotic Research ✔ Synthetic relaxin-2 B-chain analog ✔ Functionally selective RXFP1 agonist ✔ Studied for anti-fibrotic properties ✔ USA domestic shipping available Dragon Pharma B7-33 10 mg is a synthetic, single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). This peptide acts as a functionally selective agonist for the relaxin family peptide receptor 1 (RXFP1), representing a targeted tool for research into fibrosis, cardiovascular function, and tissue remodeling. Each vial contains 10 mg of lyophilized B7-33 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. B7-33 has been developed as a more stable and selective alternative to full-length relaxin-2, offering researchers a refined compound for preclinical investigations. For related research compounds, explore our peptides category and specifically SS-31 50 mg for mitochondrial function studies. What Makes B7-33 Valuable in Research? B7-33 retains the key structural elements responsible for RXFP1 activation while eliminating domains that may contribute to off-target effects or rapid clearance. Its functionally selective profile allows researchers to investigate RXFP1-mediated signaling pathways with improved specificity compared to native relaxin-2. The peptide has demonstrated promising preclinical potential in models of tissue fibrosis, cardiac remodeling, and wound healing. By activating RXFP1, B7-33 triggers downstream signaling cascades involving cAMP, MAPK, and PI3K pathways, which are linked to anti-fibrotic, anti-inflammatory, and vasoprotective effects. For researchers investigating peptide-based interventions, TB 500 offers complementary insights into tissue repair mechanisms. Current research surrounding B7-33 is available through the PubMed database, where investigators can access peer-reviewed studies on its pharmacokinetics and preclinical applications. Key Research Applications for Dragon Pharma B7-33 ✔ Investigation of RXFP1-mediated anti-fibrotic mechanisms ✔ Cardioprotection and cardiac remodeling studies ✔ Wound healing and tissue regeneration research ✔ Evaluation of relaxin-2 signaling pathways ✔ Preclinical models of fibrotic diseases For Research Purposes Only B7-33 10 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies exploring systemic inflammation, Thymosin Alpha-1 provides additional research avenues.
